|By Marketwired .||
|October 29, 2013 06:59 PM EDT||
AURORA, ON -- (Marketwired) -- 10/29/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the year ended July 31, 2013.
The following are selected highlights during the 2013 fiscal year and subsequent to year-end:
- Announced receipt, on October 28, 2013, of subscription agreements for net proceeds in excess of $4,600,000. The terms of the private placement are for the purchase of common shares at $1.15 per share and include one warrant per share at an exercise price of $1.61 and have an expiry of five years from the date of issue. The completion of the private placement is subject to approval by the Toronto Stock Exchange;
- Completed first patient enrollment and dose administration in addition to recently completing an interim review of data collected for the first four cohorts in the Company's ongoing European Phase I/II clinical study of L-DOS47 in Poland. On October 15, 2013, the Company announced the completion of an interim review of data collected to date in this study. The data to date have shown that L-DOS47 was well-tolerated for all patients within all cohorts. Duration of treatment has increased with each dose escalation, including one patient that was dosed for approximately 18 weeks without disease progression. We remain on plan for the completion of the Phase I component of the trial by the summer of 2014 and a formal analysis of the data will be conducted following collection of all data at the completion of the study.
- Completed the sale of its Rivex Pharma division on January 25, 2013;
- Implemented changes to the board of directors resulted in the appointments of Sławomir Ludwikowski, Professor Sławomir Majewski and Mr. Stacy L. Wills;
- Announced its intention to change the Company's auditors from KPMG LLP to BDO Canada LLP, effective following the completion of the Company's fiscal 2013 audit by KPMG LLP, with a transition period that commenced on June 21, 2013;
- Established Helix Polska sp.z o.o., further strengthening Canadian-Polish relationships and scientific collaboration which began in 2005, when Polish investors first became shareholders of the Company;
- Terminated the material transfer and license agreement with Merck & Co. Inc. for the Company's Topical Interferon Alpha-2b drug development program and in addition closed the Saskatoon laboratory. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company recorded a net loss and total comprehensive loss of $1,545,000 ($0.02 loss per common share) and $17,423,000 ($0.26 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
The net loss and comprehensive loss of $1,545,000 for the fiscal year ended 2013 includes a gain on sale from discontinued operations totaling $6,019,000 (2012 - $nil) and net income from discontinued operations totaling $630,000 (2012 - $1,431,000). On January 25, 2013, the Company announced the sale of its distribution business in Canada. In fiscal 2012 the Company realized a one-time charge of $6,536,000 (2013 - $nil) related to Special Committee and Settlement expenditures in connection with the 2012 AGM.
Excluding the gain on sale and the net income and total comprehensive income from discontinued operations, the Company realized a net loss and total comprehensive loss from continuing operations of $8,194,000 ($0.12 loss per common share) and $18,854,000 ($0.28 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
Research and development
Research and development costs for fiscal 2013 and 2012 totalled $5,032,000 and $7,450,000, respectively, with the bulk of the research and development costs represented by L-DOS47, Topical Interferon Alpha-2b and Corporate research and development initiatives.
L-DOS47 research and development expenses for fiscal 2013 and 2012 totalled $2,771,000 and $3,581,000, respectively. L-DOS47 research and development expenditures mainly reflect expenditures associated with the ongoing European Phase I/II clinical study in Poland.
Topical Interferon Alpha-2b research and development expenses for fiscal 2013 and 2012 totalled $774,000 and $1,631,000, respectively. Beginning in June 2012, the Company initiated a downsizing of the staff in the Saskatoon laboratory which ultimately resulted in the close of the facility in November 2012. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, strengthening the BiPhasix patent portfolio and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company also incurs corporate research and development expenses. Corporate research and development expenses totalled $1,081,000 and $1,407,000 respectively for the fiscal periods ended July 31, 2013 and 2012. The lower expenses can be attributed to a reduction in payroll expense associated with headcount reductions of corporate research and development employees in fiscal 2012 in addition to a reduction in travel, consulting and insurance related expenses.
Operating, general and administration
Operating, general and administration expenses for the fiscal years ended 2013 and 2012 totalled $3,196,000 and $4,580,000, respectively and represents a decrease of $1,384,000 (30.2%) when compared to fiscal 2012. Lower operating, general and administration expenses are the result of cost cutting measures by the Company, which include reductions related to lower legal and audit fees as a result of the Company having voluntarily surrendered its listing on the NYSE-MKT exchange in the United States, lower stock-based compensation expenses, reduced headcount and investor relations outsourcing activities.
Special committee and settlement agreement
All expenses relating to the Company's contested annual general meeting of shareholders in January 2012 and the related activities of the special committee and settlement agreement were incurred during fiscal 2012.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash reserves of $4,493,000 as at July 31, 2013 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiates through to completion. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be of the utmost importance.
The Company's consolidated fiscal 2013 and 2012 financial statements are summarized below.
Consolidated Statements of Net Loss and Comprehensive Loss (thousand $, except for per share data) 2013 2012 --------- --------- Expenses: Research and development 5,032 7,450 Operating, general & administration 3,196 4,580 Special committee & settlement agreement - 6,536 Loss (gain) on disposal and impairment on property, plant and equipment (18) 320 --------- --------- Results from operating activities before finance items (8,210) (18,886) Finance items 16 32 --------- --------- Loss and total comprehensive lossfrom continuing operations (8,194) (18,854) Net income and total comprehensive income from discontinued operations 630 1,431 Gain fro msale of discontinued operations 6,019 - --------- --------- Net loss and total comprehensive loss (1,545) (17,423) ========= ========= Loss per share from continuing operations * $ (0.12) $ (0.28) Income per share from discontinued operations * $ 0.01 $ 0.02 Gain per share from sale of discontinued operations * $ 0.09 $ - Total loss per common share * $ (0.02) $ (0.26) * Figures are for both basic and fully diluted
Consolidated Statements of Cash Flows (thousand $) 2013 2012 --------- --------- Cash provided by (used in): Net loss and total comprehensive loss (8,194) (18,854) Items not involving cash: Depreciation of property, plant and equipment 396 699 Deferred lease credit (25) (25) Stock-based compensation 241 1,347 Stock-based consideration - 69 Foreign exchange loss 9 76 Loss on disposal and impairment on property, plant and equipment (18) 320 --------- --------- (7,591) (16,368) Changes in non-cash working capital (223) 828 --------- --------- Operating activities (7,814) (15,540) Financing activities - 43 Investing activities (6) (37) Effect of exchange rate changes on cash (9) (76) --------- --------- Net decrease in cash from continuing operations (7,829) (15,610) Net increase in cash from discontinued operations 7,460 1,428 Cash beginning of the year 4,862 19,044 --------- --------- Cash end of the year 4,493 4,862 ========= ========= Consolidated Statement of Financial Position (thousand $) 2013 2012 ---------- ---------- Non current assets 677 1,493 Current assets: Prepaids 139 107 Inventory - 421 Accounts receivable 559 733 Cash 4,493 4,862 ---------- ---------- 5,191 6,123 ---------- ---------- Total assets 5,868 7,616 ========== ========== Shareholders' equity 4,920 6,224 Non current liabilities - 23 Current liabilities: Deferred lease credit 23 25 Accrued liabilities 621 694 Accounts payable 304 650 ---------- ---------- 948 1,369 ---------- ---------- Total liabilities & shareholders equity 5,868 7,616 ========== ==========
The Company's complete 2013 Consolidated Financial Statements, Management's Discussion and Analysis and Annual Information Form are being filed today with Canadian securities regulatory authorities and will be available at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's complete audited financial statements free of charge upon request.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the focus of the Company on its two drug candidates, L-DOS47 and Topical Interferon Alpha-2b (cervical lesions indication) and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's growth and future prospects being dependent on the success of one or both of L-DOS47 and Topical Interferon Alpha-2b; (iii) the Company's priority continuing to be L-DOS47; (iv) the Company's development programs for Topical Interferon Alpha-2b, DOS47 and L-DOS47, including but not limited to, extension of the drug candidates to other indications and the identification and development of further tumour-targeting antibodies for DOS47; (v) the Company's Polish Phase I/II clinical trials for L-DOS47; (vi) future expenditures, insufficiency of the Company's current cash resources and the need for financing and cost-cutting and/or cost-deferral measures; (vii) future financing requirements, the seeking of additional funding and anticipated future operating losses; and (viii) the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the gross proceeds and the net proceeds to be received in connection with the private placement. Forward-looking statements can further be identified by the use of forward-looking terminology such as "2013", "2014", ongoing" or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b (low-grade cervical lesions); that sufficient financing will be obtained in a timely manner to allow the Company to continue operations; the timely provision of services and supplies, including Interferon alpha-2b raw materials, or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support; and the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the net proceeds to be received in connection with the private placement.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all (including that the Toronto Stock Exchange may not accept the private placement and/or that the private placement may not close or that the actual amount of the net proceeds may be lower than anticipated), and that clinical trials may not commence or complete within anticipated timelines or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development or distribution activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Report, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under Helix's profile on SEDAR at www.sedar.com from time to time at. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
Tel: 905 841-2300
Email: [email protected]
"eFolder does a lot of different things but we protect data and we are focused on protecting data no matter where it resides," explained Carlo Tapia, Product Marketing Manager at eFolder, in this SYS-CON.tv interview at Cloud Expo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 1, 2015 04:00 PM EST
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Dec. 1, 2015 04:00 PM EST Reads: 501
Cloud computing is unquestionably one of the driving forces of DevOps, as the automation of operations transforms enterprise software development. DevOps, however, is more than a technology trend, as it represents a move toward silo-busting, self-organizing horizontal teams that drive business velocity. At the same time, enterprise Digital Transformation represents an upheaval across the enterprise, as customer preferences and behavior drive enterprise technology decisions. This transformation ...
Dec. 1, 2015 03:45 PM EST
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Dec. 1, 2015 03:00 PM EST Reads: 385
Most of the IoT Gateway scenarios involve collecting data from machines/processing and pushing data upstream to cloud for further analytics. The gateway hardware varies from Raspberry Pi to Industrial PCs. The document states the process of allowing deploying polyglot data pipelining software with the clear notion of supporting immutability. In his session at @ThingsExpo, Shashank Jain, a development architect for SAP Labs, discussed the objective, which is to automate the IoT deployment proces...
Dec. 1, 2015 03:00 PM EST Reads: 145
In demand-intensive mobile and web applications, an emerging pattern is to host the Systems of Engagement in the cloud (for maximum responsiveness) but keep the Systems of Record with the other important business systems in the company datacenter, often on a tightly secured mainframe. But what about the space in between? In this IBM Redpaper publication, we show that the IBM Bluemix cloud platform offers technologies that make it easy for cloud-based SoEs to securely connect to on-premises IBM...
Dec. 1, 2015 02:45 PM EST
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
Dec. 1, 2015 02:45 PM EST Reads: 447
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Dec. 1, 2015 02:15 PM EST Reads: 451
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Dec. 1, 2015 02:00 PM EST Reads: 548
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Dec. 1, 2015 01:45 PM EST Reads: 358
OpsHub, Inc. has announced enhanced support for DevOps and Migration for both Team Foundation Server and Visual Studio On-line in a heterogeneous environment. With added support for build and release entities in OpsHub Integration Manager (OIM) Microsoft customers can now leverage Visual Studio build and release services to manage DevOps processes in a heterogeneous environment. With the enhanced support customers can manage the DevOps process in Team Foundation Server while undertaking activit...
Dec. 1, 2015 01:42 PM EST
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Dec. 1, 2015 01:15 PM EST Reads: 307
SYS-CON Events announced today that Catchpoint, a global leader in monitoring, and testing the performance of online applications, has been named "Silver Sponsor" of DevOps Summit New York, which will take place on June 7-9, 2016 at the Javits Center in New York City. Catchpoint radically transforms the way businesses manage, monitor, and test the performance of online applications. Truly understand and improve user experience with clear visibility into complex, distributed online systems.Founde...
Dec. 1, 2015 12:15 PM EST
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
Dec. 1, 2015 12:00 PM EST Reads: 310
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
Dec. 1, 2015 12:00 PM EST Reads: 233